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Abstract
Introduction—Pyrazinamide (PZA) is essential in tuberculosis (TB) treatment. We describe the 
prevalence, trends and predictors of PZA resistance in Mycobacterium tuberculosis complex 
(MTBC) in the U.S.
Methods—We analyzed culture-positive MTBC cases with reported drug susceptibility tests 
(DST) for PZA in 38 jurisdictions routinely testing for PZA susceptibility from 1999-2009. 
National TB Genotyping Service data for 2004-2009 were used to distinguish Mycobacterium 
tuberculosis from Mycobacterium bovis and determine phylogenetic lineage.
Results—Overall 2.7% (2,167/79,321) of MTBC cases had PZA resistance, increasing annually 
from 2.0% to 3.3% during 1999-2009 (P<0.001), largely due to an increase in PZA 
monoresistance. PZA-monoresistant MTBC (versus drug-susceptible) was associated with age 
0-24 years (adjusted prevalence ratio [aPR]=1.50, 95% CI 1.31-1.71), Hispanic ethnicity 
(aPR=3.52, 2.96-4.18), HIV infection (aPR=1.43, 1.15-1.77), extrapulmonary disease (aPR=3.02, 
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2.60-3.52), and normal chest radiograph (aPR=1.88, 1.63-2.16), and inversely associated with 
Asian (aPR=0.59, 0.47-0.73) and Black (aPR=0.37, 0.29-0.49) race. Among multidrug-resistant 
(MDR) cases 38.0% were PZA-resistant; PZA resistance in MDR MTBC was associated with 
female sex (aPR=1.25, 1.08-1.46) and previous TB diagnosis (aPR=1.37, 1.16-1.62). Of 28,080 
cases with genotyping data, 925 (3.3%) had PZA resistance; 465/925 (50.3%) were M. bovis. In 
non-MDR M. tuberculosis cases, PZA resistance was higher in the Indo-Oceanic than the East 
Asian lineage (2.2% versus 0.9%; respectively; aPR=2.26, 1.53-3.36), but in MDR cases it was 
lower in the Indo-Oceanic lineage (22.0% versus 43.4%, respectively; aPR=0.54, 0.32-0.90).
Conclusions—Specific human and mycobacterial characteristics were associated with 
pyrazinamide-resistant MTBC, reflecting both specific subgroups of the population and 
phylogenetic lineages of the mycobacteria.
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Introduction
Pyrazinamide (PZA) is an important component of first-line and second-line regimens for 
treatment of drug-susceptible and multidrug-resistant (MDR) tuberculosis (TB) [1-3]. PZA 
has remarkable sterilizing effects, playing a unique role in killing semi-dormant TB bacilli 
not easily killed by other antibiotics[4, 5]. In drug-susceptible TB, adding PZA to rifampin 
and isoniazid allowed shortening the duration of treatment from 9 to 6 months in most 
patients[6, 7]. Recent murine and human early bactericidal activity studies of novel drug 
regimens, demonstrated PZA was essential to well-performing regimens[8-10].
Growth-based testing for PZA resistance is difficult because the drug is active only in an 
acidic microenvironment (pH 5.5), but such low pH itself inhibits the growth of 
Mycobacterium tuberculosis complex (MTBC). Further, even modest variations in inoculum 
size can alter the pH and lead to differing results[11, 12]. For these technical reasons, most 
countries and some mycobacteriology laboratories in the U.S. do not test for PZA 
susceptibility, and the global extent of PZA resistance is largely unknown. The Clinical and 
Laboratory Standards Institute recommended the BACTEC 460TB (BD, Sparks, MD, USA) 
as a reference method for PZA susceptibility testing[13]. However, in 2011 BD stopped 
producing reagents for the BACTEC 460TB system, so BACTEC Mycobacteria Growth 
Indicator Tube® (MGIT) 960 system (BD, Sparks, MD, USA) and VersaTREK® (TREK 
Diagnostic Systems, Inc., Cleveland, OH, USA) are currently the only Food and Drug 
Administration (FDA) cleared systems for PZA drug susceptibility testing (DST)[14]. These 
systems, however, may have a higher potential for false-resistant test results for PZA 
resistance than the BACTEC 460TB[12, 15].
Mycobacterium bovis, a member of MTBC, is intrinsically resistant to PZA, and PZA-
monoresistance is characteristic of M. bovis[16, 17]. In the U.S., M. bovis is transmitted to 
humans primarily by ingestion of unpasteurized dairy products and more often involves 
extrapulmonary sites of disease[18, 19].
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Because PZA will likely remain a central component in the treatment of tuberculosis for the 
foreseeable future, it is critically important to understand the epidemiology of PZA 
resistance. We describe the prevalence, trends, and risk factors for initial resistance to PZA 
among MTBC cases in the U.S.
Methods
Case reporting
The U.S. National TB Surveillance System (NTSS) at the U.S. Centers for Disease Control 
and Prevention (CDC) has collected nationwide TB incidence data since 1953[20]. We 
analyzed data on all verified, culture-positive tuberculosis cases reported by the 50 states 
and the District of Columbia through the Report of Verified Case of Tuberculosis (RVCT) 
form between 1 January 1999 and 31 December 2009. The RVCT form includes socio-
demographic and clinical information as well as DST results based on the initial positive 
culture of sputum or other specimen[21]. We examined overall and annual proportions of 
culture-positive MTBC cases with reported initial DST results for PZA. For this analysis, we 
excluded TB cases without reported DST results for isoniazid (INH), rifampin (RMP), and 
ethambutol (EMB). We also excluded states where the overall proportion of culture-positive 
TB cases with reported initial DST results to PZA was <85% during the study period.
Since data about sub-species are not available to most clinicians who treat TB (as the 
majority of the US public health labs use Accuprobe™ tests for culture identification 
reported as MTBC, and the genotype data which identifies sub-species are not immediately 
available)[22], we first characterize the epidemiology and factors associated with PZA-
resistance among cases of MTBC as a whole. Because M. bovis has intrinsic resistance to 
PZA, we distinguished MTB and M. bovis for a sub-set of MTBC cases by linking NTSS 
data to data in the National TB Genotyping Service (NTGS) database[23] from 2004, when 
the NTGS was launched, to 2009. Spacer oligonucleotide typing (spoligotyping) and 
mycobacterial interspersed repetitive unit variable number tandem repeats (MIRU-VNTR) 
techniques distinguished M. tuberculosis (Mtb) and M. bovis and identified phylogenetic 
lineages for Mtb as previously described[18, 24, 25].
Definitions
”Drug-susceptible” was defined as susceptibility to INH, RMP, EMB, and PZA. MDR was 
defined as resistance to at least INH and RMP. “PZA monoresistance” was defined as 
resistance to PZA, and susceptibility to INH, RMP and EMB. “PZA polyresistance” was 
defined as resistance to PZA with additional resistance to INH, RMP, or EMB, but not both 
INH and RMP.
“Acquired” resistance to an anti-TB drug was used to describe a case in which the DST of 
the initial isolate was recorded as “susceptible,” and that of the final isolate was recorded as 
“resistant” to the same drug.
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Statistical analyses were performed using SAS software, version 9.1 (SAS Institute Inc., 
Cary, NC). A P value of ≤0.05 was considered statistically significant. Risk factors 
associated with PZA resistance were determined among cases with MTBC, and among a 
subset of cases with infection with Mtb for 2004-2009 after matching with genotyping data. 
Prevalence ratios (PR) with 95% confidence intervals (CI) were calculated. Factors 
significant at a value of P≤0.05 and plausible epidemiological or biological associations with 
PZA resistance were included in a multivariable log-binomial regression model. We used 
backward selection starting with all candidate variables selected based on statistical criteria 
and plausible epidemiological or biological associations with PZA resistance and tested if 
the deletion of variables improved precision around point estimates in the model, repeating 
this process until no further improvement was possible.
For testing the significance of trends, we assessed the slope of the regression line using 
Poisson regression for event count data. Annual Percent Change (APC) in rates with 
confidence limits (CL) was calculated using Joinpoint Regression Program, Version 3.5.2. 
October 2011 (Statistical Research and Applications Branch, National Cancer Institute)[26].
Results
PZA resistance proportions, trends, and predictors in MTBC cases
During the 11-year study period, 125,778 culture positive MTBC cases were reported by the 
50 U.S. states and the District of Columbia (Figure 1). In 36 states and 2 other public health 
jurisdictions, the proportion of culture-positive MTBC cases that had DST results reported 
to the NTSS for PZA was ≥85% (Figure 2A), amounting to 82,672 TB cases. Of these, 
79,321 (95.9%) had DST result for all 4 first-line drugs and were included in the analysis 
(Figure 1). A total of 2,167 (2.7%) cases had initial PZA resistance: 1,441 (66.5%) were 
PZA-monoresistant, 312 (14.4%) were PZA-polyresistant and 414 (19.1%) were PZA-
resistant MDR cases. Resistance to PZA was reported in 2.2% of non-MDR cases, and 
38.0% of MDR cases. In the 14 states excluded from analysis, <50% of cases per year had a 
DST result for PZA during the study period, with the exception of 2009 (Figure 2B).
The proportion of any resistance to PZA increased significantly from 2.0% in 1999 to 3.3% 
in 2009 (P<0.001) (Figure 2A). Overall reported PZA resistance increased mainly because 
the proportion of PZA-monoresistance increased from 1.2% in 1999 to 2.5% in 2009 with 
the inflection point (“joinpoint”) for APC in 2002 (APC 1999-2002: 12.9, CL: 5.0, 19.7, 
P=0.005; APC 2002-2009: 6.0, CL: 4.3, 7.6; P<0.001), while the proportions were stable for 
PZA-polyresistance (P=0.40) and PZA resistance among MDR cases (P=0.98) (Figure 3A).
A total of 4,961 cases were alive at diagnosis, initially treated with PZA and had both initial 
and final DST result to PZA reported to the NTSS. Of 4,769 (96.1% of 4961) cases with an 
initial isolate reported as PZA-susceptible, 36 (0.8%) cases had a final DST reported as 
resistant (i.e., “acquired” resistance to PZA).
Results of descriptive analysis of predictors of monoresistance, polyresistance, and PZA 
resistance with MDR in MTBC cases are shown in Table 1. The results of multivariable 
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analysis are presented in Table 2. PZA-monoresistance (versus drug-susceptible) was 
associated with age 0-24 years (adjusted prevalence ratio [aPR]=1.50, 95% CI 1.31-1.71), 
Hispanic ethnicity (aPR=3.52, 2.96-4.18), HIV infection (aPR=1.43, 1.15-1.77), 
extrapulmonary disease (aPR=3.02, 2.60-3.52), normal chest radiograph (aPR=1.88, 
1.63-2.16), and inversely associated with Asian (aPR=0.59, 0.47-0.73) and Black 
(aPR=0.37, 0.29-0.49) race, substance use (aPR=0.80, 0.67-0.97), homelessness (aPR=0.43, 
0.28-0.65), and residence in correctional facility (aPR=0.41, 0.23-0.73). PZA-polyresistance 
(versus drug-susceptible) was associated with Hispanic ethnicity (aPR=2.49, 1.67-3.71), 
Asian (aPR=2.68, 1.82-3.96) race, previous TB diagnosis (aPR=1.78, 1.15-2.75), and 
normal chest x-ray (aPR=1.56, 1.17-2.08), and inversely associated with age ≥45 years 
(aPR=0.72, 0.56-0.92). PZA resistance in MDR cases (versus PZA-susceptible MDR) was 
associated with female sex (aPR=1.25, 1.08-1.46) and previous TB diagnosis (aPR=1.37, 
1.16-1.62).
PZA resistance proportions and trends in MTBC cases with available genotyping
The NTGS began in 2004 and by the end of 2009, genotyping results were available for 
28,080 (69.9%) of 40,151 TB cases during that period that had DST to 4 first-line drugs. 
Among the genotyped isolates, 27,428 (97.7%) were Mtb, 500 (1.8%) were M. bovis, and 
152 (0.5%) were M. africanum. Of 28,080 MTBC isolates, 925 (3.3%) had any PZA 
resistance, including 465 (50.3%) that were M. bovis. Among 27,428 Mtb isolates, 458 
(1.7%) had any resistance to PZA: 196 (42.8%) were PZA-monoresistant, 94 (20.5%) were 
PZA-polyresistant, and 168 (36.7%) were PZA-resistant MDR.
M. bovis accounted for 427 (68.3%) of 625 MTBC isolates with PZA-monoresistance, 37 
(28.2%) of 131 with reported PZA-polyresistance, and 1 (0.6%) of 169 with PZA-resistant 
MDR cases. Of 500 M. bovis isolates, 35 (7.0%) were reported as PZA-susceptible.
During 2004-2009, the annual proportion of M. bovis among MTBC isolates ranged between 
1.6-2.0% and did not significantly change over time (APC=2.1, CL: −4.6, 9.2; P=0.45) 
(Appendix. Figure 1A). Among 28,080 MTBC isolates, the proportions of PZA-
monoresistance increased significantly (P=0.004) (Figure 3B). This trend remained 
significant when M. bovis was excluded (P=0.02), although proportions of monoresistance 
to PZA were approximately three times lower in the sub-set of Mtb cases compared to 
MTBC (Figure 3C).
Predictors of PZA resistance in M. tuberculosis cases
Further analyses were limited to the subset of cases with Mtb only, excluding M. bovis and 
M. africanum, in order to understand factors associated with PZA resistance in Mtb. The 
prevalence of any PZA resistance differed by Mtb lineage: 2.9% of East Asian (110/3,857), 
2.4% of Indo-Oceanic (121/5,037), 1.8% of East African Indian (25/1,367), and 1.2% of 
Euro-American (206/17,314). The proportion of Mtb cases with Indo-Oceanic lineage 
significantly increased from 2004-2009 (APC=4.7, CL: 1.6, 7.9; P=0.01) (Appendix. 
Figure 1A). Similarly, the proportion of PZA-monoresistance significantly increased among 
Mtb cases infected with Indo-Oceanic (APC=14.2, CL: 7.0-21.8; P=0.005) and East African 
Indian (APC=38.6, CL: 1.0-90.3; P=0.05) isolates, but not among other lineages.
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The results of multivariable analysis examining the associations between clinical and 
demographic characteristics and PZA resistance in Mtb cases are presented in Table 3. The 
patient characteristics associated with PZA resistance in the subset of cases with Mtb 
differed from those for all MTBC cases. Among cases with Mtb, PZA mono-resistance was 
associated with Asian race and extrapulmonary TB. When Mtb lineage was included in the 
multivariable model, PZA monoresistance was associated with Indo-Oceanic lineage and 
was no longer associated with race or site of disease (Table 4). MDR status significantly 
modified the association between PZA resistance and Mtb lineage (P<0.001, Breslow-Day 
test). Among non-MDR cases, PZA resistance was significantly higher in the Indo-Oceanic 
(2.2%) versus East Asian (0.9%) lineage (aPR=2.26, 95% CI 1.53-3.36), while in MDR 
cases, PZA resistance was significantly lower in the Indo-Oceanic (22.0%) versus East 
Asian (43.4%) lineage (aPR=0.54, 0.32-0.90), controlling for age, race, foreign birth, HIV 
status, previous TB diagnosis and site of TB disease (Table 4).
Discussion
This large study of PZA resistance among MTBC cases in the U.S. demonstrates PZA 
resistance in 2.7% of tested MTBC cases in 38 public health jurisdictions routinely testing 
for PZA susceptibility: 2.2% of non-MDR and 38.0% of MDR cases. For comparison, 
Australia surveillance data for 2008-2009 reported PZA resistance in 1.0%-1.2% of all TB 
cases[27]. Four rounds of drug resistance surveys in South Korea conducted from 
1999-2004 showed a significant increase of PZA resistance in new cases from 0.8% to 2.1% 
[28]. In re-treatment cases, PZA resistance varied from 3.5% to 15.9% with no clear 
trend[28]. A study from Thailand indicated PZA resistance in 6% of non-MDR and 49% 
MDR TB isolates[29]. The proportion of MDR TB cases with PZA resistance ranged from 
36% to 85% in other reports[30-34].
Patient characteristics associated with PZA monoresistance among all cases with MTBC 
included Hispanic race, young age, and extrapulmonary disease. PZA monoresistance is 
typical of [0]M. bovis, and the patient characteristics we identified in this analysis are 
similar characteristics associated with TB due to M. bovis[18]. Indeed, two thirds of all 
PZA-monoresistant cases were among cases with M. bovis. In contrast, among MDR TB 
cases, PZA resistance was higher in females, in cases with previous TB, and almost 
exclusively in MTB species. Interestingly, the adjusted prevalence of PZA polyresistance, 
compared to drug-susceptible TB, included a mix of risk factors found for PZA 
monoresistance and PZA resistance in MDR, likely reflecting the broader mix of M. bovis 
and MTB species. Clinicians should be aware that patients with certain characteristics are 
more likely to have PZA-resistant TB. However, our findings confirm previous reports that 
PZA monoresistance is not a reliable marker of M. bovis[18, 35, 36]. Although not typically 
available for initial case management, species identification is important to better understand 
these findings.
Factors associated with PZA resistance among cases of Mtb are less well understood. In the 
analysis of only cases with Mtb we found that PZA monoresistance was associated with 
Asian race rather than Hispanic ethnicity, and with exclusively extrapulmonary disease. 
Because site of disease has been shown to be associated with Mtb lineage[24, 37], and these 
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lineages are differentially associated with human populations globally[38], we sought to 
determine whether the patient characteristics associated with Mtb PZA monoresistance 
reflected differences in Mtb lineage. In multivariable analysis including Mtb lineage, only 
Indo-Oceanic lineage remained significantly associated with PZA monoresistance, 
suggesting that bacterial lineage, rather than host characteristic, was the primary association. 
Globally, Indo-Oceanic lineage is primarily localized to South and Southeast Asia[38]. Our 
findings suggest two possible hypotheses for the association between PZA monoresistance 
and Indo-Oceanic lineage. First, this may reflect a biological difference by lineage in the 
propensity towards development of resistance to this drug. Second, these results would also 
be consistent with international differences in rates of PZA resistance (e.g. due to regional or 
national programmatic differences in TB treatment). Over half of all TB cases in the US are 
foreign-born[20].
In contrast to other first-line drugs (including any resistance and monoresistance to INH or 
rifampin as well as MDR)[20], the proportion of cases with reported resistance to PZA 
increased in the U.S. from 2.0% to 3.3%, 65% relative increase, largely due to an increase in 
PZA-monoresistance. Since PZA-monoresistance is characteristic of M. bovis, we assessed 
proportions of M. bovis in a sub-set of MTBC cases with genotyping results available for 
2004-2009. M. bovis did not significantly increase, and the proportion of PZA-
monoresistance increased irrespective of M. bovis. The prevalence of PZA resistance 
differed among different lineages of Mtb and the relative prevalence of these lineages 
among TB isolates was changing over time in our study population. Among MDR TB cases, 
PZA resistance was significantly higher in the East Asian lineage, while in non-MDR cases 
PZA resistance was significantly higher in the Indo-Oceanic lineage. Even though the 
proportion of PZA resistance among isolates from MDR TB cases is much higher than those 
among non-MDR cases, there were only 1,090 MDR TB cases in this analysis compared 
with 78,231 non-MDR TB cases. Both the proportion of TB cases with Indo-Oceanic 
lineage and the proportion of Indo-Oceanic cases with PZA resistance increased over time. 
Therefore, given that increasing PZA monoresistance in the U.S. does not appear to be 
related to M. bovis, it may be related to increases in the proportion of Indo-Oceanic strains. 
An increase in the proportion of Indo-Oceanic strains could be related to an increase in the 
proportion of cases in the U.S. among foreign-born persons from regions in which the Indo-
Oceanic lineage is common.
On the other hand, because MGIT 960 has been shown to have higher rates of false-resistant 
results compared to the BACTEC 460 system [15, 39], we considered that increasing 
proportions of PZA monoresistance might reflect the progressive change from BACTEC 
460TB to MGIT 960 after FDA clearance in 2002[40]. However, PZA resistance began 
increasing 3 years earlier, in 1999, and did not accelerate after 2002, suggesting the change 
in technology may not be the main reason behind the trend in PZA DST results.
Our analysis was subject to several important limitations. The main limitation is restriction 
of the analysis to 38 public health jurisdictions that routinely test for susceptibility to PZA. 
For the other 14 states the prevalence and trends may have been due to selection bias. Thus, 
the study findings may not generalize to the whole country. However, the overall proportion 
of cases with reported PZA resistance during 1999-2009 was similar in the jurisdictions 
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included in analysis (2.7%) and the 14 states excluded (2.9%); in both subsets, the 
proportions of resistance to PZA were significantly increasing. Second, the genotyping data 
was limited to 2004-2009. Genotyping in the U.S. is voluntary and coverage increased 
substantially from 51.2% to 88.2% during 2004-2010 [25]. Therefore selection bias cannot 
be excluded. Third, surveillance data have intrinsic limitations, and we could not exclude 
PZA susceptibility testing or reporting errors. For example, 7% of M. bovis cases were 
reported as PZA-susceptible, likely representing intrinsic variability of the PZA test itself 
and reporting errors[18]. PncA gene sequencing for PZA resistant strains is not routinely 
performed and surveillance data does not include this information, therefore we were not 
able to determine the correlation between phenotypic drug resistance result and PncA 
genotype.
PZA resistance in terms of absolute numbers represents a small fraction of U.S. TB cases, 
but the increasing trend in PZA resistance makes it an important public health problem 
because PZA is an essential part of treatment [1-3, 8-10]. Thus, DST for PZA is critical. The 
trend in PZA resistance calls attention to the limitations of growth-based DST for PZA, 
although meticulous attention to the size of the inoculum seems to improve its 
reproducibility[12]. Nonetheless, the development of faster, more reliable laboratory 
methods to detect PZA resistance is a priority[41, 42]. The phylogenetic diversity of Mtb 
may have important clinical consequences and implications for development of molecular 
assays for PZA resistance.
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Appendix
Figure 1A. Time trends in proportion of MTBC species and M. tuberculosis lineages 
(N=28,080)
Note. Percents are shown using total number of MTBC as a denominator.
Among 27,428 M. tuberculosis cases the phylogenetic lineages were assigned as following: 
Euro-American 17,208 (62.7%), Indo-Oceanic - 5,019 (18.3%), East Asian - 3,839 (14.0%), 
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East African Indian - 1,362 (5.0%). From 2004 to 2009, no significant changes in 
proportions of M. bovis (APC=2.1, CL: −4.6, 9.2; P=.45). The proportion of Indo-Oceanic 
lineage significantly increased (APC=4.7, CL: 1.6, 7.9; P=.01), and the proportion of Euro-
American lineage significantly decreased (APC=−2.2, CL: −3.1, −1.3; P=.003). Proportions 
of East Asian (APC=2.1, CL: −0.6, 4.8; P=.10) and East African Indian (APC=5.6, CL: 
−0.6, 12.2; P=.07) lineages did not change significantly. No significant changes in M. 
africanum proportions (APC=−5.7, CL: −17.0, 7.1; P=.27).
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In U.S. jurisdictions routinely testing Mycobacterium tuberculosis complex for 
pyrazinamide susceptibility, pyrazinamide resistance increased from 2.0% to 3.3% per 
year during 1999-2009. Changing human and mycobacterial characteristics were 
associated with this increase in resistance, including phylogenetic lineage of M. 
tuberculosis.
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Selection of MTBC cases with resistance to pyrazinamide (PZA) reported in NTSS, 
1999-2009
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Proportion of culture-positive MTBC cases with a reported PZA drug susceptibility test 
result, and proportion reported as resistant to PZA among those tested, 1999-2009 
(N=122,270)
A. Data for 36 states and 2 public health jurisdictions with ≥85% TB cases with reported 
DST result for PZA (N=82,672)
Note. Overall 2.7% of cases had resistance to PZA. Proportions of resistance to PZA 
significantly increased (APC=5.0, CL: 3.2, 6.7; P<0.001).
B. Data for 14 states with <85% TB cases with reported DST result for PZA (N=39,598)
Note. Overall 2.9% of cases had resistance to PZA. Proportions of resistance to PZA 
significantly increased (APC=5.4, CL: 1.2, 9.6; P=0.02).
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Trends in proportions of PZA resistance in MTBC and M. tuberculosis.
Percent reflects proportion of cases with specific resistance pattern among all cases tested 
for PZA drug susceptibility in each sub-set.
A. All MTBC cases, with or without available genotype, 1999-2009 (N=79,321)
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Increase in proportions of PZA-monoresistance was significant (APC during 1999-2002: 
12.9, CL: 5.0, 19.7, P=0.005; APC during 2002-2009: 6.0, CL: 4.3, 7.6; P<0.001), while no 
significant change in proportions of PZA-polyresistance (APC=2.4, CL: −3.6, 8.7; P=0.40) 
and PZA resistance in MDR (APC=−0.04, CL: −4.2, 4.3; P=0.98) observed.
B. MTBC cases with available genotype M. bovis included, 2004-2009 (N=28,080)
For monoresistance APC=9.0, CL: 2.5, 15.9; P=0.02; for polyresistance APC=0.3, CL: 
−37.7, 61.5; P=0.99; for PZA resistance in MDR TB cases APC=−4.4, CL: −19.7, 13.8; 
P=0.51; for any PZA resistance APC=5.0, CL: −4.5, 15.3; P=0.23
C. M. tuberculosis cases only, 2004-2009 (N=27,428)
For monoresistance APC=11.0, CL: 2.6, 20.1; P=0.02; for polyresistance APC=−7.2, CL: 
−31.4, 25.6; P=0.53; for PZA resistance in MDR TB cases APC=−8.5, CL: −23.2, 8.8; 
P=0.23; for any PZA resistance APC=−0.1, CL: −8.4, 9.0; P=0.97.
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Table 2
Independent predictors of PZA resistance in MTBC cases in multivariable regression analysis (N=73,138)









Sex Female vs. male - - 1.25 (1.08-1.46)
Age group, years 0-24 1.50 (1.31-1.71) 0.81 (0.57-1.15) -
45+ 0.85 (0.74-0.97) 0.72 (0.56-0.92) -
25-44 1.00 1.00 -
Race/ethnicity Hispanic 3.52 (2.96-4.18) 2.49 (1.67-3.71) -
Asian 0.59 (0.47-0.73) 2.68 (1.82-3.96) -
Black 0.37 (0.29-0.49) 0.96 (0.61-1.52) -
White/Other 1.00 1.00
Unemployed Yes vs. No/Unknown 1.27 (1.14-1.42) - -
Substance use Yes vs. No/Unknown 0.80 (0.67-0.97) - -
Homeless Yes vs. No/Unknown 0.43 (0.28-0.65) - -
Resident of
correctional facility
Yes vs. No/Unknown 0.41 (0.23-0.73) - -
HIV status Positive 1.43 (1.15-1.77) - -
Unknown 1.82 (1.61-2.06) - -
Negative 1.00 - -
Previous TB diagnosis Yes - 1.78 (1.15-2.75) 1.37 (1.16-1.62)
Unknown - 0.33 (0.05-2.38) 1.12 (0.56-2.22)
No - 1.00 1.00
Site of TB disease EPTB 3.02 (2.60-3.52) - -
EPTB&PTB 2.91 (2.50-3.39) - -
PTB 1.00 - -
Initial chest radiograph Normal 1.88 (1.63-2.16) 1.56 (1.17-2.08) -
Unknown 1.48 (1.04-2.10) 1.20 (0.54-2.70) -
Abnormal 1.00 1.00 -
Note. R=resistant, S=susceptible.
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Table 3
Independent predictors of PZA resistance in M. tuberculosis cases in multivariable regression analysis 
(N=27,428)









Age group 0-24 - 0.53 (0.26-1.09) -
25-44 - 1.00 -
45+ - 0.55 (0.35-0.84) -
Race/ethnicity Hispanic 0.95 (0.59-1.53) 1.12 (0.41-3.09) -
Asian 1.79 (1.18-2.70) 3.70 (1.49-9.22) -
Black 0.91 (0.56-1.48) 2.02 (0.75-5.47) -
White/Other 1.00 1.00 -
Foreign-born Yes - 2.37 (1.24-4.70) 0.72 (0.55-0.93)
No - 1.00 1.00
Previous TB diagnosis Yes - 2.42 (1.24-4.70) -
No - 1.00 -
Site of TB disease EPTB 1.42 (1.02-1.99) - 0.97 (0.66-1.43)
EPTB&PTB 1.24 (0.80-1.92) - 0.60 (0.34-1.05)
PTB 1.00 - 1.00
Note. R=resistant. S=susceptible
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Table 4
Association of PZA resistance with M. tuberculosis lineage in multivariable regression analysis (N=27,428)






Phylogenetic lineage EuroAmerican 1.24 (0.80-1.92) 0.83 (0.61-1.13)
IndoOceanic 2.26 (1.53-3.36) 0.54 (0.32-0.90)
East African Indian 1.17 (0.63-2.19) 0.82 (0.49-1.40)
East Asian 1.00 1.00
Age group 0-24 0.90 (0.63-1.30) 1.12 (0.83-1.52)
25-44 0.72 (0.57-0.93) 0.85 (0.64-1.13)
45+ 1.00 1.00
Race/ethnicity Hispanic 0.85 (0.52-1.38) 1.14 (0.75-1.72)
Asian 1.48 (0.89-2.46) 0.93 (0.63-1.39)
Black 1.03 (0.67-1.59) 0.87 (0.55-1.40)
White/Other 1.00 1.00
Foreign-born Yes 1.20 (0.84-1.71) 0.71 (0.53-0.97)
No 1.00 1.00
Previous TB diagnosis Yes 1.40 (0.87-2.26) 1.14 (0.86-1.52)
No 1.00 1.00
Site of TB disease EPTB 1.09 (0.82-1.46) 1.06 (0.71-1.58)
EPTB&PTB 1.05 (0.72-1.54) 0.60 (0.34-1.06)
PTB 1.00
HIV infection Yes 0.80 (0.43-1.46) 1.00 (0.65-1.52)
No/unknown 1.00 1.00
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